COLL - NASDAQ
Collegium Pharmaceutical, Inc.
$31.06
+1.9%Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
At a Glance
Live Snapshotcoll
Additional Paid-In Capital
Last Annual Value
624.95M
3-Year CAGR
5%
5-Year CAGR
4%
10-Year CAGR
11%
Collegium Pharmaceutical, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Collegium Pharmaceutical, Inc. NASDAQ:COLL | 624.95M | 3.4% | 4.5% | 5.7% | |
 Pulse Biosciences, Inc. NASDAQ:PLSE | 543.87M | 12.6% | 14.9% | 30.5% | |
 Dynavax Technologies Corporation NASDAQ:DVAX | 1.50B | -1.1% | 0.9% | 5.2% | |
 Atai Beckley Inc. NASDAQ:ATAI | 1.60B | 26.3% | 17.1% | N/A | |
 Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH | 535.38M | 3.3% | 4.9% | 6.6% | |
 MiMedx Group, Inc. NASDAQ:MDXG | 299.08M | 2.7% | 12.5% | 6.4% | |
 Nektar Therapeutics NASDAQ:NKTR | 3.85B | 2.2% | 1.8% | 6.2% | |
 Innoviva, Inc. NASDAQ:INVA | 902.73M | -6.2% | -6.5% | -3.4% | |
 GoodRx Holdings, Inc. NASDAQ:GDRX | 0.00 | N/A | N/A | N/A | |
 Pacira BioSciences, Inc. NASDAQ:PCRX | 1.06B | 2.9% | 2.5% | 6.5% |
Collegium Pharmaceutical, Inc. Fair Value Envelope
Related Guides
Continue your COLL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.